{
    "root": "35aa1572-f0fa-723c-e063-6394a90aee37",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Enalapril Maleate",
    "value": "20250521",
    "ingredients": [
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "SODIUM BICARBONATE",
            "code": "8MDF5V39QO"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "ENALAPRIL MALEATE",
            "code": "9O25354EPJ"
        }
    ],
    "indications": null,
    "contraindications": null,
    "warningsAndPrecautions": "Enalapril Maleate Tablets, USP\n                  2.5 mg: White, oval shaped scored tablet, debossed with “S 1” and scored on one side, “S” and “1” are separated by the score and plain on the other side.\n                  \n                  NDC: 70518-4210-00\n                  NDC: 70518-4210-01\n                  PACKAGING: 90 in 1 BOTTLE PLASTIC\n                  PACKAGING: 90 in 1 BOTTLE PLASTIC\n                  \n                  Storage\n                  Store at 20o to 25oC (68o to 77oF); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].\n                  Keep container tightly closed.\n                  Protect from moisture.\n                  Dispense in a tight container as per USP, if product package is subdivided.\n                  \n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions": "Enalapril maleate tablets are contraindicated in patients who are hypersensitive to this product and in patients with a history of angioedema related to previous treatment with an angiotensin-converting enzyme inhibitor and in patients with hereditary or idiopathic angioedema.\n                  Do not coadminister aliskiren with enalapril maleate tablets in patients with diabetes (see\n \n  \n                        PRECAUTIONS, Drug Interactions\n                     ).\n\n \n                  Enalapril maleate tablets are contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). Do not administer enalapril maleate tablets within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor (see\n \n  \n                        WARNINGS, Head and Neck Angioedema\n                     )."
}